We are live on ! Find out more
JNCE

Jounce Therapeutics, Inc. Common Stock
JNCE

Delisted

JNCE was delisted on the 3rd of May, 2023.

Back to rankings

124 hedge funds and large institutions have $378M invested in Jounce Therapeutics, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 40 funds opening new positions, 32 increasing their positions, 32 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 40 | Existing positions closed: 20

95% more capital invested

Capital invested by funds: $194M → $378M (+$184M)

19% more funds holding

Funds holding: 104 → 124 (+20)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 32

81% less call options, than puts

Call options by funds: $596K | Put options by funds: $3.22M

Holders
124
Holders Change
+20
Holders Change %
+19.23%
% of All Funds
2.18%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
40
Increased
32
Reduced
32
Closed
20
Calls
$596K
Puts
$3.22M
Net Calls
-$2.63M
Net Calls Change
-$2.25M

Top Buyers

Rank Fund Capital Flow
1
PHS
PFM Health Sciences
California
+$35.7M
2
Victory Capital Management
Victory Capital Management
Texas
+$25.7M
3
O
OrbiMed
New York
+$20M
4
CCM
CAAS Capital Management
New York
+$11.5M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$10.5M

Top Sellers

Rank Fund Capital Flow
1
TGI
TRV GP II
Massachusetts
-$29.6M
2
WP
Woodline Partners
California
-$6.59M
3
SI
Sofinnova Investments
California
-$4.53M
4
Bank of Montreal
Bank of Montreal
Ontario, Canada
-$1.53M
5
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$1.28M
Name Holding Trade Value Shares
Change 		Change in
Stake
Wells Fargo
26
Wells Fargo
California
$2.5M +$1.43M +130,366 +116%
SSA
27
Schonfeld Strategic Advisors
New York
$2.14M +$2.29M +208,812 New
HM
28
HealthCor Management
New York
$2.08M +$2.22M +202,585 New
Charles Schwab
29
Charles Schwab
California
$2.06M -$597K -54,500 -21%
Millennium Management
30
Millennium Management
New York
$1.83M +$1.43M +130,333 +272%
JP Morgan Chase
31
JP Morgan Chase
New York
$1.7M +$476K +43,486 +36%
Goldman Sachs
32
Goldman Sachs
New York
$1.55M +$1.27M +115,764 +326%
Mariner
33
Mariner
Kansas
$1.53M – – –
AQR Capital Management
34
AQR Capital Management
Connecticut
$1.52M -$530K -48,363 -25%
T. Rowe Price Associates
35
T. Rowe Price Associates
Maryland
$1.44M +$390K +35,630 +34%
Jacobs Levy Equity Management
36
Jacobs Levy Equity Management
New Jersey
$1.31M +$298K +27,242 +27%
N
37
Nuveen
North Carolina
$1.29M +$14.1K +1,290 +1%
CAM
38
Congress Asset Management
Massachusetts
$1.05M +$114K +10,420 +11%
Two Sigma Investments
39
Two Sigma Investments
New York
$974K +$1.04M +94,849 New
Marshall Wace
40
Marshall Wace
United Kingdom
$973K +$1.04M +94,739 New
Connor, Clark & Lunn Investment Management (CC&L)
41
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$875K -$107K -9,734 -10%
Two Sigma Advisers
42
Two Sigma Advisers
New York
$850K +$907K +82,800 New
Bank of New York Mellon
43
Bank of New York Mellon
New York
$731K -$9.52K -869 -1%
MS
44
Maven Securities
Jersey
$707K +$771K +70,396 New
Axa
45
Axa
France
$696K +$158K +14,400 +27%
First Trust Advisors
46
First Trust Advisors
Illinois
$613K +$200K +18,246 +44%
AllianceBernstein
47
AllianceBernstein
Tennessee
$574K – – –
AI
48
Atom Investors
Texas
$562K +$600K +54,762 New
State of Wisconsin Investment Board
49
State of Wisconsin Investment Board
Wisconsin
$538K -$192K -17,500 -25%
YMRC
50
Yorktown Management & Research Company
Virginia
$505K – – –
1
2
3 4 5

JNCE Hedge Fund Activity: Q1 2021 in Review

124 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Jounce Therapeutics, Inc. Common Stock (JNCE) for Q1 2021, worth a combined $378M — up 95% from $194M a quarter earlier.

Buyers outnumbered sellers: 40 funds opened new JNCE positions and 20 closed out — a net gain of 20 holders — while 32 added to existing stakes and 32 trimmed.

The largest buyer was PFM Health Sciences, opening a new position worth an estimated $35.7M. The largest seller was TRV GP II, cutting an estimated $29.6M.

  • 124 institutional investors held Jounce Therapeutics, Inc. Common Stock (JNCE) as of Q1 2021, up from 104 in Q4 2020.
  • Funds reported $378M of Jounce Therapeutics, Inc. Common Stock stock for Q1 2021, up 95% quarter-over-quarter.
  • 40 funds opened new Jounce Therapeutics, Inc. Common Stock positions in Q1 2021 and 20 closed out, a net change of +20 holders.
  • The largest Jounce Therapeutics, Inc. Common Stock buyer in Q1 2021 was PFM Health Sciences, an estimated $35.7M added.
  • The largest Jounce Therapeutics, Inc. Common Stock seller in Q1 2021 was TRV GP II, an estimated $29.6M sold.

Based on aggregated 13F filings for Q1 2021.